Quantcast

Latest Valeant Pharmaceuticals Stories

2014-04-11 08:22:40

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 11, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership,...

2014-04-10 08:28:43

DUBLIN, Apr. 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pnf52x/global ) has announced the addition of the "Global Dermatophytic Onychomycosis Therapeutics Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global Dermatophytic Onychomycosis Therapeutics market to grow at a CAGR of 7.28 percent over the period 2012-2016. One of the key factors contributing to this market...

2014-03-25 16:26:26

DUBLIN and LAVAL, Quebec, March 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Bacterial vaginosis...

2014-03-12 08:31:19

LYNDHURST, N.J., March 12, 2014 /PRNewswire/ -- Amerigen Pharmaceuticals Limited announces that its ANDA for carbidopa 25mg tablets has received final approval from the U.S. Food and Drug Administration. The product is a generic equivalent of Valeant's Lodosyn® and has been launched under an Amerigen Pharmaceuticals label. John Lowry, Amerigen's President & CEO commented: "We are very pleased to receive our first ANDA approval. This product was entirely self-developed and...

2014-03-06 12:27:00

The pharmaceutical company is committed to donating a portion of its Medicis® and Obagi® product sales every quarter for a combined donation goal of $1 million in one year. NEW YORK, March 6, 2014 /PRNewswire/ -- Valeant Pharmaceuticals North America, LLC, today announced it has donated $250,000 to the National Coalition Against Domestic Violence (NCADV). The donation is a reflection of Valeant's ongoing support and commitment to the wellbeing of women, and is the first of four checks the...

2014-02-27 12:27:41

LONDON, Feb. 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Parkinson's Disease Market 2012-2016 TechNavio's analysts forecast the Global Parkinson's Disease market to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinson's Disease market has also been witnessing the transition toward using drugs that have new...

2014-02-05 16:28:03

LAVAL, Quebec, Feb. 5, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, February 27, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2013 fourth quarter and full year. The dial-in number to participate on this call is (877) 876-8393, confirmation code 68673247. International callers should dial (973)...

2014-02-03 08:27:23

LAVAL, Quebec, Feb. 3, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and...

2014-01-31 08:25:29

LAVAL, Quebec, Jan. 31, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration (FDA) for its Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA has approved our new strength of Retin-A Micro® as this gives health care providers and patients a new...

2014-01-23 16:25:32

LAVAL, Quebec, Jan. 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the completion of the previously announced transaction in which a wholly-owned subsidiary of Valeant Pharmaceuticals International ("VPI") would acquire Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. On January 23, 2014, Valeant announced that it had...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'